Mycostatin is prescribed in the management of infection and contains nystatin, an antifungal active ingredient with a long history of clinical use. The brand is registered in 16 countries, a mid-range international footprint that places it within reach of travellers and expatriates in several distinct regions but not on every pharmacy shelf worldwide.
Nystatin is one of the more established antifungal molecules in international pharmacopoeias, and Mycostatin is one of several brand names under which the ingredient reaches patients globally. The structured indication section further down this page details the registered uses recognised in the markets where Mycostatin is authorised, and that block is the right reference point for a reader trying to confirm whether a specific clinical situation falls within those registered indications.
The countries where Mycostatin is marketed span a wide geographic mix — examples include Indonesia, Egypt, Italy, New Zealand, and Sweden. That spread means the same brand can appear in very different regulatory and packaging contexts, from Northern European markets to the Middle East and Southeast Asia. Travellers who have been prescribed Mycostatin in one of these countries and then move to another may or may not encounter the identical brand, but nystatin itself is widely available internationally under various commercial names and as a generic.
Other antifungal medications exist under different active ingredients in essentially every regulated market in the world, although molecules within the broader antifungal category are not freely interchangeable. A local pharmacist is well placed to identify regional nystatin-containing products or to flag whether a different antifungal would be the appropriate equivalent. Any decision to start, stop, or substitute this medication is one for a healthcare provider familiar with the individual patient.
No information provided.
Nystatin topical preparations are contraindicated in patients with a history of hypersensitivity to any of their components.
The frequency of adverse events reported in patients using Mycostatin (nystatin) ® preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General.)
Nystatin is not absorbed from intact skin or mucous membrane.
No information provided.
PRECAUTIONS GeneralNystatin, topical preparations should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.
If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.
Laboratory TestsIf there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.
Carcinogenesis, Mutagenesis, Impairment of FertilityNo long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.
Pregnancy: Teratogenic EffectsCategory C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.
Nursing MothersIt is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.
Pediatric UseSafety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION.)
Geriatric UseClinical studies with MYCOSTATIN (Nystatin) Cream and MYCOSTATIN (Nystatin) Topical Powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Very moist lesions are best treated with the topical dusting powder.
MYCOSTATIN (nystatin) ® CreamAdults and Pediatric Patients (Neonates and Older): Apply liberally to affected areas twice daily or as indicated until healing is complete.
MYCOSTATIN (nystatin) ® Topical PowderAdults and Pediatric Patients (Neonates and Older): Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
The frequency of adverse events reported in patients using Mycostatin (nystatin) ® preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General.)
DRUG INTERACTIONSNo information provided.
Mycostatin is prescribed in the management of infection, with nystatin's clinical role traditionally focused on fungal infections rather than bacterial or viral ones. The structured indication block further down this page lists the registered uses recognised by national regulators in the markets where Mycostatin is sold. A healthcare provider can confirm whether a particular presentation of infection falls within those registered indications.
Mycostatin contains nystatin as its active ingredient. Nystatin is one of the longer-established antifungal molecules and is sold internationally under several brand names as well as in generic form. The molecule itself is the same regardless of the commercial label, although formulations and presentations can differ between countries depending on local regulatory practice and manufacturer.
Mycostatin is registered in 16 countries, spread across Europe, the Middle East, Southeast Asia, and Oceania. Representative markets include Indonesia, Egypt, Italy, New Zealand, Sweden, Lebanon, and Taiwan. If your country is not on this list, a local pharmacist can usually confirm whether nystatin is available in that market under a different brand name or as a generic equivalent.
Nystatin circulates worldwide under several brand names beyond Mycostatin, particularly in markets where multiple manufacturers supply the molecule in parallel. Other antifungal medications also exist under different active ingredients, although they are not freely interchangeable — molecules vary in spectrum and clinical positioning. To identify a regional nystatin-containing product, search the active ingredient on Pill2Trip or ask a pharmacist locally.
Mycostatin is generally treated as a prescription product, though the exact regulatory status of nystatin-containing preparations varies between countries. Travellers and expatriates may find that requirements for obtaining the same molecule differ noticeably from one market to another. Any decision to start, continue, or substitute Mycostatin should be made with a healthcare provider familiar with the patient's situation rather than improvised at a pharmacy counter.
